Tukysa (Tucatinib)

Brand Name: Tukysa
Innovator Brand Name: Tukysa
API: Tucatinib
Dosage Form: 60/120 Tablets
Strength: 50/150mg
Manufacturer Name: Seattle Genetics, Inc.

Get Price


Tukysa (Tucatinib Tablets) is a kinase inhibitor used in combination with trastuzumab and capecitabine to treat adult patients with advanced unresectable or metastatic HER2-Positive Breast Cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

Dosage: The recommended dosage of Tukysa is 300 mg, which should be taken orally twice daily along with trastuzumab and capecitabine until the disease is progressive or unacceptable toxicity occurs. Swallow the tablets of Tukysa whole and not to chew, crush, or split prior to swallowing. Do not ingest tablets if it is broken, cracked, or not otherwise intact. Administer the tukysa dosage around 12 hours apart and at the persistent time each day with or without a meal. In case the patient vomits or misses a dose of Tukysa, the patient should take the next dose at its usual scheduled time. When given along with Tukysa, the recommended dosage of capecitabine is 1000 mg/m2 orally twice daily taken within 30 minutes after a meal. Tukysa and capecitabine can be taken at the same time.

Side Effects:  The most commonly reported tukysa side effects (incidence ≥20%) include:

  • diarrhea
  • nausea
  • fatigue
  • hepatotoxicity
  • vomiting
  • stomatitis
  • decreased appetite
  • abdominal pain
  • headache
  • anemia
  • rash
  • palmar-plantar erythrodysesthesia

Warnings and Precautions:

  • Tucatinib 150 Mg Tablet has been associated with severe diarrhea. Instruct patients on how to manage diarrhea and to inform their health specialist immediately if there is any change in bowel.
  • Monitor ALT, AST, and bilirubin prior to starting tucatinib 50 mg / 150 mg, every 3 weeks during treatment, and as clinically indicated.
  • Tucatinib has been associated with severe hepatotoxicity. Patients should report signs and symptoms of liver dysfunction to their health specialist immediately.
  • The tukysa fda label drug can cause fetal harm if administered to a pregnant woman. Females of reproductive age should use apt contraception during treatment and for at least 7 days following the last dose.
  • Women should not breastfeed during treatment with Tucatinib and for at least 7 days following the last dose.

More info

Storage: Store at controlled room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F). Dispense tucatinib tablets to patients in the original container only. Store in the original container in order to protect from moisture. Replace cap securely every time following opening. Do not discard desiccant. Once opened, use within 3 months. Discard any unused tablets 3 months after opening the bottle. Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship the TUKYSA at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the TUKYSA 50 mg Tablets. Buying Procedure: In order to buy TUKYSA, you can contact us at our TOLL-FREE Number: 1800 889 1064 or on WhatsApp number +919310090915 or an Email to us at: info@theindianpharma.com along with the legitimate ID Proof, Standard Prescription and Medical Reports. Conclusions: In heavily pretreated patients with HER2 +Ve metastatic breast cancer, including those with brain metastases, addition of tucatinib with trastuzumab and capecitabine resulted in better PFS and OS outcomes than adding placebo; the probability of diarrhea and elevated aminotransferase levels were greater with tucatinib.


What is Tukysa? Tukysa is a brand-name prescription drug that contains the API Tucatinib. It’s a targeted therapy aimed to treat HER2+ breast cancer. When was Tukysa FDA approved? On April 17, 2020, Tukysa was approved by the US Food and Drug Administration. What does Tukysa contain as an active substance? The medication Tukysa specifically contains the active substance Tucatinib. How is Tukysa administered? Tukysa is an oral medicine administered twice daily. How much does tukysa cost? The tukysa price in India usually can vary depending on the wholesaler/pharmacy you visit. Tukysa is available as a brand name drug only, a generic version is not yet available. Has a generic version of Tukysa been approved? No, There is currently no therapeutically equivalent version of Tukysa approved in the US. What is the best price for Tucatinib? Please contact Toll-free: +91 1800 889 1064 |+919310090915 for tucatinib price in India. We take the guarantee of quality and delivery anywhere in the world as per the buyer’s requirements. Can I get Tukysa (Tucatinib) even if I am not based in India? The Indian Pharma helps patients in accessing or importing Tukysa (Tucatinib), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.